This review will address therapeutic options for HER2-positive breast cancer patients who progress after trastuzumab, attempting to outline the most favorable algorithm for clinicians utilizing FDA-approved regimens as well as novel therapeutics that are currently under study (Figure 1). The gene discussed is ERBB2; the disease is breast carcinoma.